Market Place
Sourcing Support
Targeting Breast Cancer with Ribociclib, Leading CDK 4/6 Inhibitor
28 Mar 2025 //
PRESS RELEASE
Olema Oncology Presents Updated Palazestrant Data at SABCS
10 Dec 2024 //
GLOBENEWSWIRE
Novartis Kisqali Nataled Data Show Durable Breast Cancer Benefits
10 Dec 2024 //
GLOBENEWSWIRE
Novartis Kisqali Natalee Data Show Durable Early Breast Cancer
10 Dec 2024 //
PR NEWSWIRE
Novartis Kisqali® Approved for HR+/HER2- Early Breast Cancer
27 Nov 2024 //
GLOBENEWSWIRE
Olema to Present Data on Palazestrant + Ribociclib at Symposium
25 Nov 2024 //
GLOBENEWSWIRE
Novartis ribociclib recognized as Category 1 preferred breast cancer treatment
24 Oct 2024 //
GLOBENEWSWIRE
Novartis Gets Positive CHMP Opinion For Kisqali® In Breast Cancer
18 Oct 2024 //
GLOBENEWSWIRE
Novartis Gets Broad FDA Approval For Kisqali In Early Breast Cancer
18 Sep 2024 //
PR NEWSWIRE
Relay Therapeutics Announces Positive Data For RLY-2608
09 Sep 2024 //
GLOBENEWSWIRE
Novartis gears up for key expansions of 3 cancer drugs
24 Apr 2024 //
FIERCE PHARMA
Novartis pauses enrollment for Kisqali breast cancer trials to align with nitrosamine guidelines
11 Apr 2024 //
PRESS RELEASE
Alembic Pharma gets tentative USFDA nod for breast cancer drug
02 Apr 2024 //
ECONOMICTIMES
Kisqali analysis reinforces 25% reduction in risk of recurrence of breast cancer
08 Dec 2023 //
GLOBENEWSWIRE
Olema Announces Palazestrant Demonstrates Combinability with CDK4/6 Inhibitors
05 Dec 2023 //
GLOBENEWSWIRE
Novartis puts Kisqali`s peak sales potential at above $7B
28 Nov 2023 //
FIERCE PHARMA
Novartis showcases significant data updates from Kisqali, iptacopan and Scemblix
20 Nov 2023 //
GLOBENEWSWIRE
Novartis Kisqali analysis reinforces reduction in risk of breast cancer
20 Oct 2023 //
GLOBENEWSWIRE
Novartis drug cuts recurrence risk by 25% in early-stage breast cancer
03 Jun 2023 //
REUTERS
Olema Oncology to Present at the 2023 Jefferies Healthcare Conference
30 May 2023 //
GLOBENEWSWIRE
MSN Lab`s Generic Ribociclib Receives Receives Approval in the U.S.
09 May 2023 //
FDA
MSN Lab Generic Letrozole:Ribociclib Receives Approval in the U.S
01 May 2023 //
FDA
Novartis to present new data across oncology portfolio including Kisqali Ph III
26 Apr 2023 //
GLOBENEWSWIRE
Novartis` Kisqali, Pluvicto top list of investor concerns
25 Apr 2023 //
FIERCE PHARMA
Novartis buoyed by trial success in early-stage breast cancer
28 Mar 2023 //
REUTERS
Natalee PIII trial demonstrates ribociclib reduces the risk of breast cancer
27 Mar 2023 //
GLOBENEWSWIRE
Novartis Kisqali PFS benefit for pre- and perimenopausal patients with HR+/HER2
06 Dec 2022 //
PRNEWSWIRE
Kesimpta surges as Kisqali starts to ramp at Novartis
19 Jul 2022 //
FIERCEPHARMA
Kisqali increases OS in advanced breast cancer patients by 12 months
09 Mar 2022 //
EUROPEANPHARMACEUTICALREVIEW
Novartis & SOLTI collaborate on HARMONIA, phase III study of Kisqali vs Ibrance
21 Sep 2021 //
PHARMABIZ
Novartis to pit Kisqali against Ibrance in head-to-head trial
20 Sep 2021 //
FIERCEPHARMA
Ribociclib/Endocrine Therapy Improves OS Regardless of Age in Advanced
07 May 2021 //
ONCLIVE
Novartis` KISQALI product monograph in Canada now includes MONALEESA-3 data
18 Mar 2021 //
BIOSPACE
Novartis Kisqali® demonstrates nearly five years median overall survival in MBC
08 Dec 2020 //
PRNEWSWIRE
Novartis` MONALEESA-7 KISQALI® (ribociclib) study demonstrated significant
02 Nov 2020 //
NEWSWIRE
Novartis Kisqali receives highest rating of any CDK4/6 inhibitor on the ESMO
21 Sep 2020 //
PHARMABIZ
Novartis announces new late-breaking ofatumumab data at EAN
26 May 2020 //
GLOBENEWSWIRE
AllianceRx Walgreens Prime studies the use of cyclin kinase 4/6 inhibs
11 May 2020 //
PR NEWSWIRE
Novartis touts survival edge in Kisqali`s TV debut
04 Mar 2020 //
FIERCE PHARMA
Novartis’ Kisquali bests AZ’ Faslodex in breast cancer trial
13 Dec 2019 //
PHARMA TIMES
Novartis, Eli Lilly marquee positive survival data for CDK 4/6 franchises
29 Sep 2019 //
ENDPTS
FDA Warns of Possible Interstitial Lung Disease, Pneumonitis,Breast Cancer Drugs
16 Sep 2019 //
CANCERTHERAPYADVISOR
Three Breast Cancer Drugs: FDA Warns of Rare but Serious Lung Inflammation
13 Sep 2019 //
RAPS
NICE U-turn for Kisqali in breast cancer
18 Jul 2019 //
PHARMATIMES
Novartis’ Kisqali, trailing Lilly’s Verzenio, nabs limited NICE backing
17 Jul 2019 //
FIERCE PHARMA
U.K. drug discovery startup Healx taps GSK, Astex alum as CSO
11 Jul 2019 //
FIERCE BIOTECH
Novartis’ Kisqali hits endpoints in Phase III breast cancer trial
04 Jun 2019 //
PHARMATIMES
What to watch for, including Keytruda, Lynparza, KRAS and more
31 May 2019 //
FIERCE PHARMA
Novartis exploring Saudi Arabia for production of cancer drugs
10 May 2019 //
FIERCE PHARMA
Novartis’ Kisqali hit with NICE rejection
10 Apr 2019 //
PHARMATIMES
NICE rejects Novartis` struggling breast cancer drug Kisqali
10 Apr 2019 //
FIERCE PHARMA
NICE nod for Lilly’s breast cancer drug Verzenio via CDF
02 Apr 2019 //
PMLIVE
NICE nod for Lilly’s breast cancer drug Verzenio via CDF
01 Apr 2019 //
PMLIVE
EMA committee recommends approval for 4 medicine
20 Nov 2018 //
PHARMABIZ
NICE rejects Eli Lilly`s Verzenio for breast cancer in draft guidance
19 Oct 2018 //
PHARMA FILE
Lilly gets EMA nod for Verzenio in breast cancer
03 Oct 2018 //
PM LIVE
Novartis considers filings for PI3K drug in breast cancer
24 Aug 2018 //
PMLIVE
Merck`s Keytruda scores paramount nod in lung cancer
21 Aug 2018 //
FIERCE PHARMA
Merck ‘real-time’ OK for Keytruda offers a peek at FDA`s data highway
21 Aug 2018 //
ENDPTS
